Expression and methylation status of BTG2, PPP1CA, and PEG3 genes in colon adenocarcinoma cell lines: promising treatment targets Gene methylation of BTG2, PPP1CA, and PEG3 in colon cancer
Gastroenterology and Hepatology from Bed to Bench,
Vol. 15 No. 4 (2022),
3 October 2022
Aim: This study investigated the association between methylation status and expression levels of BTG2, PPP1CA, and PEG3 genes in colon cancer.
Background: Aberrant DNA methylation is one of the most important epigenetic modifications in the development of cancer. Evidence indicates that hypermethylation of various tumor suppressor genes could be a potential mechanism of colon tumorigenesis.
Methods: The expression levels of BTG2, PPP1CA, and PEG3 genes were evaluated in HT-29/219, HCT116, SW48, SW742, SW480, and LS180 cell lines using quantitative Real-Time PCR. The methylation status of BTG2 and PPP1CA was determined by methylation-specific PCR (MSP) method, and the methylation pattern of PEG3 was evaluated by bisulfite sequencing PCR (BSP). To investigate the effect of methylation on the expression of these genes, all colon cancer cell lines were treated by 5-Azacitidine (5-Aza) and/or Trichostatin A (TSA).
Results: The expression levels of BTG2, PPP1CA, and PEG3 were highly heterogeneous and quantitatively correlated to their promoter methylation status in the studied colon cancer cell lines. Treatment by 5-Aza and/or TSA increased the expression of the above-named genes in colon cancer cell lines.
Conclusion: Overall, it seems that BTG2, PPP1CA, and PEG3 act as tumor suppressor genes in colon cancer, and methylation is a potential mechanism for their loss of expression. Therefore, these genes may be considered as suitable targets for demethylation approaches and, eventually, colon cancer treatment. Combined treatment by 5-Aza and TSA may be a promising therapeutic strategy for colon cancer treatment. Further studies may contribute to confirm these results.
- Colon cancer; BTG2; PPP1CA; PEG3; DNA methylation
How to Cite
Mattiuzzi C, Sanchis-Gomar F, Lippi G. Concise update on colorectal cancer epidemiology. Ann Transl Med 2019;7.
Mokarram P, Zamani M, Kavousipour S, Naghibalhossaini F, Irajie C, Sarabi MM, et al. Different patterns of DNA methylation of the two distinct O6-methylguanine-DNA methyltransferase (O 6-MGMT) promoter regions in colorectal cancer. Mol Biol Rep 2013;40:3851-7.
Hosseini SV, Mojtahedi Z, Beizavi Z, Khazraei H, Zamani M. Relationship between Arg753Gln Toll-like receptor 2 and Asp299Gly Toll-like receptor 4 genetic variations and susceptibility to colorectal cancer in southern Iran. Arch Biol Sci 2018;70:775-9.
Zamani M, Hosseini SV, Mokarram P. Epigenetic biomarkers in colorectal cancer: premises and prospects. Biomarkers 2018;23:105-14.
Okugawa Y, Grady WM, Goel A. Epigenetic alterations in colorectal cancer: emerging biomarkers. Gastroenterology 2015;149:1204-25.
Li J, Sun Ch, Cai W, Li J, Rosen B P, Chen J. Insights into S-adenosyl-l-methionine (SAM)-dependent methyltransferase related diseases and genetic polymorphisms. Mutat Res Rev Mutat Res 2021;788:108396.
Baylin SB, Jones PA. Epigenetic determinants of cancer. CSH Perspect Biol 2016;8:a019505.
Aslani S, Mahmoudi M, Karami J, Jamshidi AR, Malekshahi Z, Nicknam MH. Epigenetic alterations underlying autoimmune diseases. Autoimmunity 2016;49:69-83.
Wise IA, Charchar FJ. Epigenetic modifications in essential hypertension. Int J Mol Sci 2016;17:451.
Khyzha N, Alizada A, Wilson MD, Fish JE. Epigenetics of atherosclerosis: emerging mechanisms and methods. Trends Mol Med 2017;23:332-47.
Ordovás JM, Smith CE. Epigenetics and cardiovascular disease. Nat Rev Cardiol 2010;7:510.
Abdolmaleky HM, Thiagalingam S, Wilcox M. Genetics and epigenetics in major psychiatric disorders. Am J Pharmacogenomics 2005;5:149-60.
Drong A, Lindgren C, McCarthy M. The genetic and epigenetic basis of type 2 diabetes and obesity. Clin Pharmacol Ther 2012;92:707-15.
Shen S, Zhang R, Guo Y, Loehrer E, Wei Y, Zhu Y, et al. A multi‐omic study reveals BTG2 as a reliable prognostic marker for early‐stage non‐small cell lung cancer. Mol Oncol 2018;12:913-24.
Zhou L, Liang X, Zhang L, Yang L, Nagao N, Wu H, et al. MiR-27a-3p functions as an oncogene in gastric cancer by targeting BTG2. Oncotarget 2016;7:51943.
Zhang Y-j, Wei L, Liu M, Li J, Zheng Y-q, Gao Y, et al. BTG2 inhibits the proliferation, invasion, and apoptosis of MDA-MB-231 triple-negative breast cancer cells. Tumor Biol 2013;34:1605-13.
Coppola V, Musumeci M, Patrizii M, Cannistraci A, Addario A, Maugeri-Sacca M, et al. BTG2 loss and miR-21 upregulation contribute to prostate cell transformation by inducing luminal markers expression and epithelial–mesenchymal transition. Oncogene 2013;32:1843-53.
Huang C-S, Zhai J-M, Zhu X-X, Cai J-P, Chen W, Li J-H, et al. BTG2 is Down-regulated and inhibits Cancer stem cell-like features of side population cells in hepatocellular carcinoma. Digest Dis Sci 2017;62:3501-10.
Struckmann K, Schraml P, Simon R, Elmenhorst K, Mirlacher M, Kononen J, et al. Impaired expression of the cell cycle regulator BTG2 is common in clear cell renal cell carcinoma. Cancer Res 2004;64:1632-8.
Yang CH, Yue J, Pfeffer SR, Handorf CR, Pfeffer LM. MicroRNA miR-21 regulates the metastatic behavior of B16 melanoma cells. J Biol Chem 2011;286:39172-8.
Liu M, Wu H, Liu T, Li Y, Wang F, Wan H, et al. Regulation of the cell cycle gene, BTG2, by miR-21 in human laryngeal carcinoma. Cell Res 2009;19:828-37.
Zhang L, Huang H, Wu K, Wang M, Wu B. Impact of BTG2 expression on proliferation and invasion of gastric cancer cells in vitro. Mol Biol Rep 2010;37:2579-86.
Li B, Liu X, Wu G, Liu J, Cai S, Wang F, et al. MicroRNA-934 facilitates cell proliferation, migration, invasion and angiogenesis in colorectal cancer by targeting B-cell translocation gene 2: Running title: miR934 facilitates the progression of colorectal cancer. Bioengineered 2021;12: 9507-19.
Feng W, Marquez RT, Lu Z, Liu J, Lu KH, Issa JPJ, et al. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down‐regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer 2008;112:1489-502.
Kim J, Frey WD, He H, Kim H, Ekram MB, Bakshi A, et al. PEG3 mutational effects on reproduction and placenta-specific gene families. PloS one 2013;8:83359.
Dowdy SC, Gostout BS, Shridhar V, Wu X, Smith DI, Podratz KC, et al. Biallelic methylation and silencing of paternally expressed gene 3 (PEG3) in gynecologic cancer cell lines. Gynecol Oncol 2005;99:126-34.
Chen MY, Liao WSL, Lu Z, Bornmann WG, Hennessey V, Washington MN, et al. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy. Cancer 2011;117:4424-38.
Maegawa S, Yoshioka H, Itaba N, Kubota N, Nishihara S, Shirayoshi Y, et al. Epigenetic silencing of PEG3 gene expression in human glioma cell lines. Mol Carcinog 2001;31:1-9.
Zhou T, Lin W, Zhu Q, Renaud H, Liu X, Li R, et al. The role of PEG3 in the occurrence and prognosis of colon cancer. OncoTargets Ther 2019;12:6001.
Aggen JB, Nairn AC, Chamberlin R. Regulation of protein phosphatase-1. Chem Biol 2000;7:13-23.
Castro ME, Ferrer I, Cascón A, Guijarro MV, Lleonart M, Cajal SRy, et al. PPP1CA contributes to the senescence program induced by oncogenic Ras. Carcinogenesis 2008;29:491-9.
Vafadar A, Mokaram P, Erfani M, Yousefi Z, Farhadi A, Elham Shirazi T, et al. The effect of decitabine on the expression and methylation of the PPP1CA, BTG2, and PTEN in association with changes in miR‐125b, miR‐17, and miR‐181b in NALM6 cell line. J Cell Biochem 2019;120:13156-67.
Yang Y, Yin W, Wu F, Fan J. Combination of azacitidine and trichostatin A decreased the tumorigenic potential of lung cancer cells. OncoTargets Ther 2017;10:2993.
Capobianco E, Mora A, La Sala D, Roberti A, Zaki N, Badidi E, et al. Separate and combined effects of DNMT and HDAC inhibitors in treating human multi-drug resistant osteosarcoma HosDXR150 cell line. PloS one 2014;9:95596.
Al-Rayyan N, Litchfield LM, Ivanova MM, Radde BN, Cheng A, Elbedewy A, et al. 5-Aza-2-deoxycytidine and trichostatin A increase COUP-TFII expression in antiestrogen-resistant breast cancer cell lines. Cancer Lett 2014;347:139-50.
Erfani M, Hosseini SV, Mokhtari M, Zamani M, Tahmasebi K, Alizadeh Naini M, et al. Altered ARID1A expression in colorectal cancer. BMC cancer 2020;20:1-13.
Vymetalkova V, Vodicka P, Vodenkova S, Alonso S, Schneider-Stock R. DNA methylation and chromatin modifiers in colorectal cancer. Mol Aspects Med 2019;69:73-92.
Chen G, Han N, Li G, Li X, Li G, Li Z, et al. Time course analysis based on gene expression profile and identification of target molecules for colorectal cancer. Cancer Cell Int 2016;16:22.
Ou J-N, Torrisani J, Unterberger A, Provençal N, Shikimi K, Karimi M, et al. Histone deacetylase inhibitor Trichostatin A induces global and gene-specific DNA demethylation in human cancer cell lines. Biochem Pharmacol 2007;73:1297-307.
- Abstract Viewed: 58 times
- PDF Downloaded: 56 times